NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01134523,Regimens Comparison for Breast Cancers of Positive Lymph Nodes,https://clinicaltrials.gov/study/NCT01134523,,UNKNOWN,To compare the efficacy and safety of EC-T and ET regimen as adjuvant treatment of breast cancer patients with positive lymph nodes,NO,Breast Cancer,"DRUG: Epirubicin, CTX, Paclitaxel|DRUG: Epirubicin, Paclitaxel","PFS, 5 years after all the recuiment","OS, 5 years after all the adjuvent treatments|Safety, Assessing for Hematology and Non-hematology toxicities, including all SAEs., 5 years after all the recruiment",,Chinese Academy of Medical Sciences,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1000,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CH-BC-006,2010-05,2018-05,2020-05,2010-06-02,,2013-03-15,"Cancer Institute & Hospital. Chinese Academy of Medical Sciences, Beijing, 100021, China",
